CNTB - Connect Biopharma to Present at Two Upcoming Investor Conferences

Connect Biopharma Holdings Limited (Nasdaq: CNTB), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of asthma and chronic obstructive pulmonary disease (COPD), has announced its participation in two upcoming investor conferences. These events highlight the company's commitment to advancing its innovative therapies, particularly its lead candidate, Rademikibart™.

The first event is the Leerink Partners Global Biopharma Conference, scheduled for March 12, 2025, where Connect Biopharma management will engage in a fireside chat at 1:40 p.m. ET. The second conference is the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference on March 27, 2025, featuring another fireside chat at 2:30 p.m. ET. Investors and interested parties can access live webcasts of both events on the company's website in the Investors section. Archived replays will be available for around 90 days after each event, allowing broader access to the discussions.

Connect Biopharma, based in San Diego, is making strides with Rademikibart™, a next-generation anti-interleukin-4-receptor alpha (IL-4R?) antibody. This promising treatment aims to address both acute and chronic care needs in asthma and COPD patients. Notably, Rademikibart™ has shown encouraging safety and efficacy results in Phase 2 trials, boasting a rapid onset of action within 24 hours. The company identifies a significant market opportunity by targeting approximately 1 million asthma and 1.3 million COPD patients in the U.S. who experience acute exacerbations annually.

As Connect Biopharma continues to advance its clinical pipeline, these conferences offer a platform to communicate its progress and future goals to the investment community. For more information, visit www.connectbiopharm.com or contact their investor relations team.

Connect Biopharma Holdings Limited (Nasdaq: CNTB) is poised for an exciting period as the company prepares to present at two notable investor conferences this March. Investors should closely monitor these developments, as the upcoming events represent a prime opportunity for Connect Biopharma to bolster its visibility and attract potential investments.

Participating in the Leerink Partners Global Biopharma Conference and the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference allows Connect Biopharma to engage with a diverse audience of investors, analysts, and healthcare professionals. The company's focus remains on their lead product, Rademikibart™, a next-generation anti-IL-4R monoclonal antibody targeting acute exacerbations in asthma and COPD. The significant market for these conditions, with over 2.3 million Americans affected annually, underscores the potential upside of Rademikibart™ as the company progresses through its clinical trials.

So far, Phase 2 studies have yielded promising efficacy and safety results, highlighting Rademikibart's rapid onset of action—often within just 24 hours. Positive updates from these conferences can significantly influence investor sentiment, particularly if management shares encouraging data or insights regarding ongoing trials. Such news could lead to increased buying interest, resulting in stock price appreciation.

Investors should also consider the competitive landscape. Biopharma companies focusing on respiratory diseases are gaining traction, highlighting the critical need for innovative therapies. Monitoring industry trends and regulatory updates alongside Connect Biopharma’s announcements will be essential.

In summary, the forthcoming investor presentations are crucial moments for Connect Biopharma. Investors should stay informed and be prepared to act based on new developments from the conferences, with an eye on the broader market's response to Rademikibart’s clinical progress and potential commercial success.